NCT05772208View on ClinicalTrials.gov

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

PHASE3RecruitingINTERVENTIONAL

Enrollment

459

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2028

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

Camrelizumab

camrelizumab 200mg q3w

DRUG

Nimotuzumab

nimotuzumab 200mg qw

DRUG

neoadjuvant chemotherapy and CCRT

the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.

Trial Locations (1)

200032

RECRUITING

Fudan Universtiy Shanghai Cancer Centre, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER